Search

Your search keyword '"Mufti GJ"' showing total 4 results
Start Over Author "Mufti GJ" Publication Type Electronic Resources

Refine your results

4 results on '"Mufti GJ"'

1. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Author

Unnikrishnan, A, Papaemmanuil, E, Beck, D, Deshpande, NP, Verma, A, Kumari, A, Woll, PS, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE, Unnikrishnan, A, Papaemmanuil, E, Beck, D, Deshpande, NP, Verma, A, Kumari, A, Woll, PS, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, and Pimanda, JE

Published
2017

2. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Author

Unnikrishnan, A ; https://orcid.org/0000-0001-5168-8755, Papaemmanuil, E, Beck, D, Deshpande, NP ; https://orcid.org/0000-0002-0324-8728, Verma, A, Kumari, A, Woll, PS, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI ; https://orcid.org/0000-0002-4876-7230, Tursky, ML ; https://orcid.org/0000-0001-7777-4491, Huang, Y ; https://orcid.org/0000-0002-7003-3110, Ali, Z, Olivier, J ; https://orcid.org/0000-0002-3144-4507, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR ; https://orcid.org/0000-0002-5700-5684, MacKenzie, KL ; https://orcid.org/0000-0003-2996-1617, Wong, JWH ; https://orcid.org/0000-0003-2953-7728, Campbell, PJ, Pimanda, JE ; https://orcid.org/0000-0002-0509-8962, Unnikrishnan, A ; https://orcid.org/0000-0001-5168-8755, Papaemmanuil, E, Beck, D, Deshpande, NP ; https://orcid.org/0000-0002-0324-8728, Verma, A, Kumari, A, Woll, PS, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI ; https://orcid.org/0000-0002-4876-7230, Tursky, ML ; https://orcid.org/0000-0001-7777-4491, Huang, Y ; https://orcid.org/0000-0002-7003-3110, Ali, Z, Olivier, J ; https://orcid.org/0000-0002-3144-4507, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR ; https://orcid.org/0000-0002-5700-5684, MacKenzie, KL ; https://orcid.org/0000-0003-2996-1617, Wong, JWH ; https://orcid.org/0000-0003-2953-7728, Campbell, PJ, and Pimanda, JE ; https://orcid.org/0000-0002-0509-8962

Published
2017

3. Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia

Author

Giagounidis, A, Mufti, GJ, Fenaux, P, Sekeres, MA, Szer, J, Platzbecker, U, Kuendgen, A, Gaidano, G, Wiktor-Jedrzejczak, W, Hu, K, Woodard, P, Yang, AS, Kantarjian, HM, Giagounidis, A, Mufti, GJ, Fenaux, P, Sekeres, MA, Szer, J, Platzbecker, U, Kuendgen, A, Gaidano, G, Wiktor-Jedrzejczak, W, Hu, K, Woodard, P, Yang, AS, and Kantarjian, HM

Abstract

BACKGROUND: Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (AML). In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/intermediate-1-risk MDS. METHODS: Patients who had thrombocytopenia with low-risk/intermediate-1-risk MDS (N = 250) were randomized 2:1 to receive romiplostim or placebo weekly for 58 weeks. RESULTS: The primary endpoint- the number of clinically significant bleeding events (CSBEs) per patient-had a hazard ratio for romiplostim:placebo of 0.83 (95% confidence interval, 0.66-1.05; P = .13). CSBEs were reduced significantly in the romiplostim group for patients who had baseline platelet counts ≥20 × 10(9) /L (P < .0001). For patients who had baseline platelet counts <20 × 10(9) /L, there was no difference in the number of CSBEs, but the platelet transfusion rates were higher in the placebo group (P < .0001), which may have affected the overall CSBE results in this group with severe thrombocytopenia. The incidence of bleeding events was reduced significantly in the romiplostim group (relative risk, 0.92), as were protocol-defined platelet transfusions (relative risk, 0.77). Platelet response rates according to 2006 International Working Group criteria were higher for the group that received romiplostim (odds ratio, 15.6). On the basis of interim data, an independent data monitoring committee advised halting study drug because of concerns regarding excess blasts and AML rates with romiplostim (interim hazard ratio, 2.51). At 58 weeks, the AML rates were 6% in the romiplostim group and 4.9% in the placebo group (hazard ratio, 1.20; 95% confidence interval, 0.38-3.84), and the overall survival rates were similar. CONCLUSIONS: Romiplostim treatment in patients with low-risk/intermediate-1-risk MDS increased platelet counts and decreased the number of bleeding events and platelet

Published
2014

4. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Author

van de Loosdrecht, AA, Alhan, C, Bene, MC, Della Porta, MG, Drager, AM, Feuillard, J, Font, P, Germing, U, Haase, D, Homburg, CH, Ireland, R, Jansen, JH (Joop), Kern, W, Malcovati, L, te Marvelde, Jeroen, Mufti, GJ, Ogata, K, Orfao, A, Ossenkoppele, GJ, Porwit, A, Preijers, FW, Richards, SJ, Schuurhuis, GJ, Subira, D, Valent, P, van der Velden, Vincent, Vyas, P, Westra, AH, de Witte, TM, Wells, DA, Loken, MR, Westers, TM, van de Loosdrecht, AA, Alhan, C, Bene, MC, Della Porta, MG, Drager, AM, Feuillard, J, Font, P, Germing, U, Haase, D, Homburg, CH, Ireland, R, Jansen, JH (Joop), Kern, W, Malcovati, L, te Marvelde, Jeroen, Mufti, GJ, Ogata, K, Orfao, A, Ossenkoppele, GJ, Porwit, A, Preijers, FW, Richards, SJ, Schuurhuis, GJ, Subira, D, Valent, P, van der Velden, Vincent, Vyas, P, Westra, AH, de Witte, TM, Wells, DA, Loken, MR, and Westers, TM

Abstract

The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter Row cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34(+) precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results